ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Protalex Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia
April 10, 2018FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Protalex, Inc. (OTCQB: PRTX)today announced that the Company has enrolled the first of three patients in cohort four of its U.S./U.K. -
Protalex Awarded Grant from FDA Office of Orphan Products Development for PRTX-100
August 21, 2017Protalex announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the Company a $403,000 grant to support future clinical development activity of PRTX-100 as a treatment for Immune Thrombocytopenia (IT
Pharma Sources Insight January 2025
